Shield Therapeutics plc (AIM:STX)
London · Delayed Price · Currency is GBP · Price in GBX 6.70
+0.30 (4.69%)
Jun 19, 2026, 8:13 AM GMT
Shield Therapeutics Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Shield Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of 17p. The average 1-year stock price forecast is 148.81% higher than the current stock price, while the lowest is 12p (+79.10%) and the highest is 23p (+243.28%).
Price Target: 17p (+148.81%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Shield Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
74.81M
from 49.70M
Increased by 50.53%
Revenue Next Year
100.94M
from 74.81M
Increased by 34.92%
EPS This Year
-0.00
from -0.02
EPS Next Year
0.01
from -0.00
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 78.1M | ||
| Avg | 74.8M | ||
| Low | 68.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 57.1% | ||
| Avg | 50.5% | ||
| Low | 37.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -0.00 | ||
| Low | -0.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |